A Randomized Multicenter Comparison of Basiliximab and Muromonab (OKT3) in Heart Transplantation: SIMCOR Study

Segovia, Javier; Rodriguez-Lambert, Jose L.; Crespo‐Leiro, María G.; Almenar, Luís; Roig, E.; Gómez-Sánchez, Miguel Ángel; Lage, E.; Manito, Nicolás; Alonso‐Pulpón, Luis

doi:10.1097/01.tp.0000209924.00229.e5

Cited by 57 publications

(35 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the setting of induction (rather than rescue of acute rejection), recent results of a randomized trial of muromonab versus the chimeric anti-CD25 mAb basiliximab and retrospective analyses examining muromonab versus basiliximab in heart transplantation recipients suggest that targeting CD25, a component of the interleukin-2 receptor on activated T and B cells, confers similar antirejection efficacy but with lower complication rates. 45,46 In recent years, clinical evaluation of mAbs for cardiovascular indications has intensified outside the area of heart transplantation, including the prevention of thrombosis and treatment of hypercholesterolemia, as discussed below. Abciximab, which binds glycoprotein IIb/IIIa and prevents platelet adhesion to fibrinogen and corresponding platelet aggregation, significantly reduces the short-term reinfarction rate and mortality when used as adjunctive therapy for ST-segment-elevation myocardial infarction.…”

Section: Clinical Update In Cardiologymentioning

confidence: 99%

Evolution and Emergence of Therapeutic Monoclonal Antibodies

2013

View full text Add to dashboard Cite

Section: Clinical Update In Cardiologymentioning

confidence: 99%

Evolution and Emergence of Therapeutic Monoclonal Antibodies

2013

View full text Add to dashboard Cite

“…may increase the risk of lymphoma in the first year after solid organ transplantation (46 (50). The use of IL-2 receptor antagonists has increased significantly over the past five years, likely due to the low incidence of acute adverse effects.…”

Section: • the Use Of Okt3 And Atg (But Not Anti-il-2 Receptor Antibomentioning

confidence: 99%

Canadian Cardiovascular Society Consensus Conference update on cardiac transplantation 2008: Executive Summary

Haddad

Isaac

Légaré

et al. 2009

Canadian Journal of Cardiology

View full text Add to dashboard Cite

“…Table 22 summarizes adverse reactions reported with basiliximab. [252][253][254][255][256][257][258][259][260][261][262][263] Table 23 summarizes the use of basiliximab in two studies of lung transplant patients . 265,266 Table 24 summarizes 16 studies in which the drug was administered for nonpulmonary indications.…”

Section: Il-2 Receptor Antagonistsmentioning

confidence: 99%

“…265,266 Table 24 summarizes 16 studies in which the drug was administered for nonpulmonary indications. [252][253][254][255][256][257][258][259][260][261][262][263][267][268][269][270] These studies were included in the table because they provided signifi cant information regarding toxicity.…”

Section: Il-2 Receptor Antagonistsmentioning

confidence: 99%

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Baughman

Meyer

Nathanson

et al. 2012

Chest

View full text Add to dashboard Cite

Objectives: Immunosuppressive pharmacologic agents prescribed to patients with diffuse interstitial and infl ammatory lung disease and lung transplant recipients are associated with potential risks for adverse reactions. Strategies for minimizing such risks include administering these drugs according to established, safe protocols; monitoring to detect manifestations of toxicity; and patient education. Hence, an evidence-based guideline for physicians can improve safety and optimize the likelihood of a successful outcome. To maximize the likelihood that these agents will be used safely, the American College of Chest Physicians established a committee to examine the clinical evidence for the administration and monitoring of immunosuppressive drugs (with the exception of corticosteroids) to identify associated toxicities associated with each drug and appropriate protocols for monitoring these agents. Methods: Committee members developed and refi ned a series of questions about toxicities of immunosuppressives and current approaches to administration and monitoring. A systematic review was carried out by the American College of Chest Physicians. Committee members were supplied with this information and created this evidence-based guideline. Conclusions: It is hoped that these guidelines will improve patient safety when immunosuppressive drugs are given to lung transplant recipients and to patients with diffuse interstitial lung disease. CHEST 2012; 142(5):e1S-e111SAbbreviations: ACCP 5 American College of Chest Physicians; ALT 5 alanine aminotransferase; ATG 5 antithymocyte globulin; CHF 5 congestive heart failure; CMV 5 cytomegalovirus; CNI 5 calcineurin inhibitor; COI 5 confl ict of interest; CsA 5 cyclosporin A; FDA 5 US Food and Drug Administration; HBV 5 hepatitis B virus; HMG-CoA 5 b -hydroxy-bmethylglutaryl-coenzyme A; HSP 5 Health and Science Policy Committee; IL2RA 5 IL-2 receptor a ; ILD 5 interstitial lung disease; IPF 5 idiopathic pulmonary fi brosis; ITP 5 idiopathic thrombocytopenia purpura; LAM 5 lymphangioleiomyomatosis; MESNA 5 sodium 2-sulfonylethanesufonate; MPA 5 mycophenolic acid; mTOR 5 mammalian target of rapamycin; PTLD 5 posttransplant lymphoproliferative disease; RCT 5 randomized controlled trial; SIRS 5 systemic infl ammatory response syndrome; TNF 5 tumor necrosis factor; TPMT 5 thiopurine methyltransferase

show abstract

A Randomized Multicenter Comparison of Basiliximab and Muromonab (OKT3) in Heart Transplantation: SIMCOR Study

Abstract: In this HTx study, induction therapy with BAS was safer and better tolerated than OKT3, without significant differences in efficacy outcomes.

Cited by 57 publications

References 31 publications

Evolution and Emergence of Therapeutic Monoclonal Antibodies

Evolution and Emergence of Therapeutic Monoclonal Antibodies

Canadian Cardiovascular Society Consensus Conference update on cardiac transplantation 2008: Executive Summary

Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients

Contact Info

Product

Resources

About